NYSE:NVS - Novartis Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $108.50
Forecasted Upside: 23.35 %
Number of Analysts: 12
Breakdown:
2 Sell Ratings
3 Hold Ratings
7 Buy Ratings
0 Strong Buy Ratings

^$87.96 As of 05/7/2021 01:00 AM ET

▲ +0.61 (0.70%)

1 month | 3 months | 12 months

Get New Novartis Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for NVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$108.50

▲ +23.35% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for Novartis in the last 3 months. The average price target is $108.50, with a high forecast of $112.00 and a low forecast of $105.00. The average price target represents a 23.35% upside from the last price of $87.96.

Hold

The current consensus among 12 polled investment analysts is to hold stock in Novartis. This rating has held steady since March 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
4 buy ratings
4 hold ratings
3 sell ratings

Ratings as of

11/16/2019

0 strong buy ratings
3 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

2/14/2020

0 strong buy ratings
5 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

5/14/2020

0 strong buy ratings
5 buy ratings
2 hold ratings
2 sell ratings

Ratings as of

8/12/2020

0 strong buy ratings
6 buy ratings
1 hold ratings
2 sell ratings

Ratings as of

11/10/2020

0 strong buy ratings
7 buy ratings
2 hold ratings
2 sell ratings

Ratings as of

2/8/2021

0 strong buy ratings
7 buy ratings
3 hold ratings
2 sell ratings

Ratings as of

4/9/2021

0 strong buy ratings
7 buy ratings
3 hold ratings
2 sell ratings

Ratings as of

5/9/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
4/28/2021	JPMorgan Chase & Co.	Reiterated Rating	Underweight		Low	i
4/28/2021	Oddo Bhf	Upgrade	Neutral ➝ Outperform		Low	i
4/19/2021	UBS Group	Reiterated Rating	Buy		Low	i
3/23/2021	Societe Generale	Reiterated Rating	Buy		Low	i
3/22/2021	Sanford C. Bernstein	Initiated Coverage	Market Perform		Medium	i
3/16/2021	Argus	Reiterated Rating	Buy ➝ Hold		Low	i
3/10/2021	Argus	Downgrade	Buy ➝ Hold		Low	i
2/2/2021	Morgan Stanley	Reiterated Rating	Overweight		Low	i
2/1/2021	Cowen	Downgrade	Outperform ➝ Market Perform	$110.00 ➝ $105.00	Low	i
1/22/2021	Barclays	Reiterated Rating	Underweight		Medium	i
1/15/2021	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy		Low	i
1/8/2021	Morgan Stanley	Reiterated Rating	Overweight		Low	i
12/3/2020	Argus	Boost Price Target		$100.00 ➝ $112.00	Low	i
11/25/2020	UBS Group	Reiterated Rating	Buy		Low	i
11/10/2020	JPMorgan Chase & Co.	Reiterated Rating	Underweight		Low	i
9/29/2020	Berenberg Bank	Initiated Coverage	Buy		Medium	i
9/23/2020	Oddo Bhf	Downgrade	Buy ➝ Neutral		Low	i
9/10/2020	UBS Group	Upgrade	Neutral ➝ Buy		Low	i
9/1/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight		High	i
8/12/2020	JPMorgan Chase & Co.	Reiterated Rating	Underweight		Low	i
7/28/2020	Morgan Stanley	Reiterated Rating	Equal Weight		Low	i
6/15/2020	Citigroup	Upgrade	Neutral ➝ Buy		Low	i
5/11/2020	UBS Group	Reiterated Rating	Neutral		Medium	i
4/29/2020	JPMorgan Chase & Co.	Reiterated Rating	Underweight		Low	i
4/29/2020	Barclays	Reiterated Rating	Underweight		Low	i
4/23/2020	Morgan Stanley	Reiterated Rating	Equal Weight		Low	i
4/3/2020	The Goldman Sachs Group	Reiterated Rating	Buy	$116.00	High	i Rating by Keyur Parekh at The Goldman Sachs Group, Inc.
3/10/2020	Morgan Stanley	Upgrade	Underweight ➝ Equal Weight		Low	i
2/25/2020	Guggenheim	Downgrade	Buy ➝ Neutral		High	i
2/17/2020	Citigroup	Downgrade	Buy ➝ Neutral		Low	i
10/25/2019	Cowen	Reiterated Rating	Buy	$100.00	Low	i
8/29/2019	Jefferies Financial Group	Reiterated Rating	Buy		Low	i
7/23/2019	Argus	Boost Price Target	Buy	$105.00	Low	i
7/23/2019	Kepler Capital Markets	Downgrade	Buy ➝ Hold		Low	i
7/5/2019	JPMorgan Chase & Co.	Reiterated Rating	Sell		Medium	i
4/25/2019	Liberum Capital	Upgrade	Hold ➝ Buy		Low	i
4/24/2019	Guggenheim	Upgrade	Neutral ➝ Buy	$79.16	Medium	i
4/10/2019	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$82.50 ➝ $82.52	Low	i
1/29/2019	JPMorgan Chase & Co.	Reiterated Rating	Sell		Low	i
1/16/2019	JPMorgan Chase & Co.	Reiterated Rating	Sell		Low	i
1/2/2019	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight		Medium	i
12/20/2018	Credit Suisse Group	Downgrade	Sell		Low	i Rating by Matthew Weston at Credit Suisse Group AG
12/11/2018	Jefferies Financial Group	Reiterated Rating	Buy ➝ Buy	$105.00	Low	i
12/7/2018	Barclays	Downgrade	Equal Weight ➝ Sell		Low	i
12/2/2018	Cowen	Upgrade	Market Perform ➝ Outperform	$88.03	Low	i
11/28/2018	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i
11/26/2018	Cowen	Upgrade	Market Perform ➝ Outperform	$100.00	Low	i
11/16/2018	The Goldman Sachs Group	Upgrade	Neutral ➝ Conviction-Buy		Low	i
11/6/2018	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i
10/23/2018	Wolfe Research	Initiated Coverage	Outperform		Medium	i
10/18/2018	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i
10/11/2018	JPMorgan Chase & Co.	Reiterated Rating	Neutral		High	i
10/10/2018	The Goldman Sachs Group	Reiterated Rating	Neutral		Medium	i
10/8/2018	Guggenheim	Initiated Coverage	Neutral ➝ Neutral		Low	i
9/11/2018	BNP Paribas	Upgrade	Underperform ➝ Neutral		Low	i
9/11/2018	Exane BNP Paribas	Upgrade	Underperform ➝ Neutral		Low	i
9/11/2018	Citigroup	Upgrade	Neutral ➝ Buy		Low	i
9/10/2018	Bank of America	Upgrade	Underperform ➝ Buy	$74.71	Low	i
7/19/2018	Barclays	Upgrade	Underweight ➝ Equal Weight		Low	i
7/19/2018	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i
7/19/2018	DZ Bank	Reiterated Rating	Buy		Low	i
5/29/2018	HSBC	Downgrade	Buy ➝ Hold		Low	i
5/25/2018	Credit Suisse Group	Upgrade	Underperform ➝ Neutral		Low	i
5/17/2018	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i
4/20/2018	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Neutral		Low	i
4/10/2018	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Neutral		Low	i
4/9/2018	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i
1/18/2018	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i
1/15/2018	UBS Group	Reiterated Rating	Neutral		Low	i
1/2/2018	Nord/LB	Reiterated Rating	Neutral		Medium	i
12/27/2017	Nord/LB	Reiterated Rating	Neutral		Low	i
12/6/2017	Bank of America	Downgrade	Neutral ➝ Underperform		Low	i
10/31/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		N/A	i
10/25/2017	Barclays	Downgrade	Equal Weight ➝ Underweight		N/A	i Rating by Emmanuel Papadakis at Barclays PLC
10/24/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		N/A	i
10/23/2017	SVB Leerink	Boost Price Target	Market Perform	$89.00 ➝ $91.00	N/A	i
10/10/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		N/A	i
9/26/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i
9/5/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i
8/29/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i
8/9/2017	Cowen	Set Price Target	Hold	$90.00	Medium	i Rating by Steve Scala at Cowen Inc
7/26/2017	Morgan Stanley	Upgrade	Underweight ➝ Overweight		Low	i
7/18/2017	Cowen	Reiterated Rating	Hold		Low	i Rating by Steve Scala at Cowen Inc
7/17/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i
7/11/2017	Cowen	Set Price Target	Hold	$77.00	Low	i Rating by Steve Scala at Cowen Inc
7/10/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i
7/5/2017	Credit Suisse Group	Downgrade	Neutral ➝ Underperform	$82.25	Medium	i Rating by Rebekah Harper at Credit Suisse Group AG
6/22/2017	SVB Leerink	Reiterated Rating	Market Perform	$83.00	Low	i
6/22/2017	Barclays	Upgrade	Underweight ➝ Equal Weight		Low	i Rating by Emmanuel Papadakis at Barclays PLC
6/22/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		High	i Rating by Richard Vosser at JPMorgan Chase & Co.
6/16/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i Rating by Richard Vosser at JPMorgan Chase & Co.
6/8/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i Rating by Richard Vosser at JPMorgan Chase & Co.
6/6/2017	Morgan Stanley	Reiterated Rating	Sell		Low	i
6/2/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i Rating by Richard Vosser at JPMorgan Chase & Co.
5/30/2017	UBS Group	Reiterated Rating	Neutral		N/A	i
5/24/2017	UBS Group	Reiterated Rating	Neutral		N/A	i
4/18/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i Rating by Richard Vosser at JPMorgan Chase & Co.
4/5/2017	Cowen	Downgrade	Outperform ➝ Market Perform	$87.00 ➝ $77.00	Low	i
3/23/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i Rating by Richard Vosser at JPMorgan Chase & Co.
3/22/2017	The Goldman Sachs Group	Reiterated Rating	Neutral		Low	i
3/14/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low	i Rating by Richard Vosser at JPMorgan Chase & Co.
3/9/2017	Liberum Capital	Initiated Coverage	Buy ➝ Buy		Low	i
3/7/2017	Barclays	Initiated Coverage	Underweight		N/A	i
3/7/2017	Societe Generale	Upgrade	Hold ➝ Buy	$73.82 ➝ $74.37	N/A	i
3/7/2017	BNP Paribas	Downgrade	Neutral ➝ Underperform		N/A	i
1/31/2017	Argus	Upgrade	Hold ➝ Buy		N/A	i
1/25/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		N/A	i Rating by Richard Vosser at JPMorgan Chase & Co.
1/19/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		N/A	i Rating by Richard Vosser at JPMorgan Chase & Co.
1/17/2017	Berenberg Bank	Downgrade	Buy ➝ Hold		N/A	i
1/11/2017	Credit Suisse Group	Downgrade	Outperform ➝ Neutral		N/A	i
1/9/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Neutral		N/A	i
1/3/2017	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral		N/A	i
12/13/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i
11/18/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i
11/10/2016	Argus	Upgrade	Hold ➝ Buy	$85.00	N/A	i
10/27/2016	Societe Generale	Reiterated Rating	Hold		N/A	i
10/24/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i
10/16/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i
10/10/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i
10/10/2016	Chardan Capital	Lower Price Target	Buy	$95.00 ➝ $92.00	N/A	i
9/20/2016	Chardan Capital	Initiated Coverage	Buy	$95.00	N/A	i
9/13/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i
8/25/2016	Argus	Reiterated Rating	Hold		N/A	i Rating by John Eade at Argus
7/19/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i
7/13/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i
7/12/2016	Bank of America	Reiterated Rating	Hold		N/A	i Rating by Graham Parry at Bank of America Co.
5/26/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i
5/24/2016	Citigroup	Reiterated Rating	Neutral		N/A	i
5/19/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i
5/18/2016	Bank of America	Reiterated Rating	Hold		N/A	i Rating by Graham Parry at Bank of America Co.
5/18/2016	Citigroup	Reiterated Rating	Neutral		N/A	i
5/13/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i

(Data available from 5/9/2016 forward)

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Today's Range

Now: $87.96

$87.69

$88.17

50 Day Range

MA: $86.87

$85.18

$88.66

52 Week Range

Now: $87.96

$77.04

$98.52

Volume

2,048,575 shs

Average Volume

1,981,185 shs

Market Capitalization

$201.31 billion

P/E Ratio

28.47

Dividend Yield

2.38%

Beta

0.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Novartis?

The following sell-side analysts have issued stock ratings on Novartis in the last twelve months: Argus, Barclays PLC, Berenberg Bank, Citigroup Inc., Cowen Inc, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Morgan Stanley, Oddo Bhf, Sanford C. Bernstein, Societe Generale, and UBS Group AG.
View the latest analyst ratings for NVS.

What is the current price target for Novartis?

2 Wall Street analysts have set twelve-month price targets for Novartis in the last year. Their average twelve-month price target is $108.50, suggesting a possible upside of 23.4%. Argus has the highest price target set, predicting NVS will reach $112.00 in the next twelve months. Cowen Inc has the lowest price target set, forecasting a price of $105.00 for Novartis in the next year.
View the latest price targets for NVS.

What is the current consensus analyst rating for Novartis?

Novartis currently has 2 sell ratings, 3 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVS, but not buy more shares or sell existing shares.
View the latest ratings for NVS.

What other companies compete with Novartis?

Other companies that are similar to Novartis include Johnson & Johnson, Roche, Pfizer, Abbott Laboratories, AbbVie, Merck & Co., Inc., Eli Lilly and, Novo Nordisk A/S, Bristol-Myers Squibb, AstraZeneca, Sanofi, GlaxoSmithKline, CSL, Zoetis and Bayer Aktiengesellschaft.

How do I contact Novartis' investor relations team?

Novartis' physical mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company's listed phone number is 41-61-324-1111 and its investor relations email address is [email protected] The official website for Novartis is www.novartis.com.